Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or ≤ 1 Conventional Synthetic DMARD

Next Previous
Search
Trial Profile

A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or ≤ 1 Conventional Synthetic DMARD

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms APTITUDE; FOREMOST
  • Sponsors Amgen; Celgene Corporation

    • Most Recent Events

    • 15 Jun 2024 Results assessing the efficacy of APR on impact of disease as measured by PsAID-12 total score in pts with early oligoarticular PsA presented at the 25th Annual Congress of the European League Against Rheumatism
    • 15 Jun 2024 Results assessing efficacy and safety of apremilast vs placebo in pts with early oligo PsA presented at the 25th Annual Congress of the European League Against Rheumatism
    • 12 Jun 2024 According to an Amgen media release, the company announced the presentation of data of this trial at the European Alliance of Associations for Rheumatology's (EULAR) 2024 Congress, June 12-15 in Vienna.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top